B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Daniel El Fassi; Claus H Nielsen; Steen J Bonnema; Hans K Hasselbalch; Laszlo Hegedüs

doi:http://dx.doi.org/10.1210/jc.2006-2388

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Daniel El Fassi, Claus H Nielsen, Steen J Bonnema, Hans K Hasselbalch, Laszlo Hegedüs

108 Citationer (Scopus)

Abstract

Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Endocrinology and Metabolism
Vol/bind	92
Udgave nummer	5
Sider (fra-til)	1769-72
Antal sider	4
ISSN	0021-972X
DOI	https://doi.org/10.1210/jc.2006-2388
Status	Udgivet - 1 maj 2007

Adgang til dokumentet

http://dx.doi.org/10.1210/jc.2006-2388

Citationsformater

@article{b4c5f2b8b9754555a2ea719d23e4b71b,

title = "B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study",

abstract = "Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.",

author = "{El Fassi}, Daniel and Nielsen, {Claus H} and Bonnema, {Steen J} and Hasselbalch, {Hans K} and Laszlo Heged{\"u}s",

year = "2007",

month = may,

day = "1",

doi = "http://dx.doi.org/10.1210/jc.2006-2388",

language = "English",

volume = "92",

pages = "1769--72",

journal = "Journal of Clinical Endocrinology and Metabolism",

issn = "0021-972X",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

AU - El Fassi, Daniel

AU - Nielsen, Claus H

AU - Bonnema, Steen J

AU - Hasselbalch, Hans K

AU - Hegedüs, Laszlo

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.

AB - Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.

U2 - http://dx.doi.org/10.1210/jc.2006-2388

DO - http://dx.doi.org/10.1210/jc.2006-2388

M3 - Journal article

SN - 0021-972X

VL - 92

SP - 1769

EP - 1772

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

IS - 5

ER -

B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater